Clinical and Radiographic Outcomes in Patients Diagnosed with Early Rheumatoid Arthritis in the First Years of the Biologic Treatment Era: A 10-year Prospective Observational Study

REFERENCES

1. 1.↵
   1. Smolen JS,
   2. Aletaha D,
   3. Koeller M,
   4. Weisman MH,
   5. Emery P

   . New therapies for treatment of rheumatoid arthritis. Lancet 2007;370:1861–74.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Cush JJ

   . Early rheumatoid arthritis — is there a window of opportunity? J Rheumatol Suppl. 2007 Nov;80:1–7.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Smolen JS,
   2. Aletaha D,
   3. Bijlsma JW,
   4. Breedveld FC,
   5. Boumpas D,
   6. Burmester G,
   7. et al.

   Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631–7.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Elkayam O,
   2. Pavelka K

   . Biologic registries in rheumatology: lessons learned and expectations for the future. Autoimmun Rev 2012;12:329–36.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Klareskog L,
   2. van der Heijde D,
   3. de Jager JP,
   4. Gough A,
   5. Kalden J,
   6. Malaise M,
   7. et al.

   Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675–81.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Emery P,
   2. Breedveld FC,
   3. Hall S,
   4. Durez P,
   5. Chang DJ,
   6. Robertson D,
   7. et al.

   Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008;372:375–82.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Breedveld FC,
   2. Weisman MH,
   3. Kavanaugh AF,
   4. Cohen SB,
   5. Pavelka K,
   6. van Vollenhoven R,
   7. et al.

   The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26–37.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Hetland ML,
   2. Christensen IJ,
   3. Tarp U,
   4. Dreyer L,
   5. Hansen A,
   6. Hansen IT,
   7. et al.

   Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010;62:22–32.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Kievit W,
   2. Adang EM,
   3. Fransen J,
   4. Kuper HH,
   5. van de Laar MA,
   6. Jansen TL,
   7. et al.

   The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data. Ann Rheum Dis 2008;67:1229–34.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Kievit W,
    2. Fransen J,
    3. Oerlemans AJ,
    4. Kuper HH,
    5. van der Laar MA,
    6. de Rooij DJ,
    7. et al.

    The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. Ann Rheum Dis 2007;66:1473–8.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Bazzani C,
    2. Filippini M,
    3. Caporali R,
    4. Bobbio-Pallavicini F,
    5. Favalli EG,
    6. Marchesoni A,
    7. et al.

    Anti-TNFalpha therapy in a cohort of rheumatoid arthritis patients: clinical outcomes. Autoimmun Rev 2009;8:260–5.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Iannone F,
    2. Gremese E,
    3. Gallo G,
    4. Sarzi-Puttini P,
    5. Botsios C,
    6. Trotta F,
    7. et al.

    High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: data from GISEA, the Italian biologics register. Clin Rheumatol 2014;33:31–7.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Ornbjerg LM,
    2. Ostergaard M,
    3. Boyesen P,
    4. Krogh NS,
    5. Thormann A,
    6. Tarp U,
    7. et al.

    Impact of tumour necrosis factor inhibitor treatment on radiographic progression in rheumatoid arthritis patients in clinical practice: results from the nationwide Danish DANBIO registry. Ann Rheum Dis 2013;72:57–63.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. Descalzo MA,
    2. Carbonell J,
    3. Gonzalez-Alvaro I,
    4. Sanmarti R,
    5. Balsa A,
    6. Hernandez-Barrera V,
    7. et al.

    Effectiveness of a clinical practice intervention in early rheumatoid arthritis. Arthritis Care Res 2012;64:321–30.

    OpenUrl
15. 15.↵
    1. Arnett FC,
    2. Edworthy SM,
    3. Bloch DA,
    4. McShane DJ,
    5. Fries JF,
    6. Cooper NS,
    7. et al.

    The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. van Gestel AM,
    2. Anderson JJ,
    3. van Riel PL,
    4. Boers M,
    5. Haagsma CJ,
    6. Rich B,
    7. et al.

    ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology. J Rheumatol 1999;26:705–11.

    OpenUrlPubMed
17. 17.↵
    1. Pincus T,
    2. Summey JA,
    3. Soraci SA Jr,
    4. Wallston KA,
    5. Hummon NP

    . Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 1983;26:1346–53.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. van der Heijde D

    . How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 1999;26:743–5.

    OpenUrlPubMed
19. 19.↵
    1. Aga AB,
    2. Lie E,
    3. Uhlig T,
    4. Olsen IC,
    5. Wierod A,
    6. Kalstad S,
    7. et al.

    Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000–2010. Ann Rheum Dis 2015;74:381–8.

    OpenUrlAbstract/FREE Full Text
20. 20.↵
    1. Nell VP,
    2. Machold KP,
    3. Eberl G,
    4. Stamm TA,
    5. Uffmann M,
    6. Smolen JS

    . Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology 2004;43:906–14.

    OpenUrlAbstract/FREE Full Text
21. 21.↵
    1. Mottonen T,
    2. Hannonen P,
    3. Korpela M,
    4. Nissila M,
    5. Kautiainen H,
    6. Ilonen J,
    7. et al.

    Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 2002;46:894–8.

    OpenUrlCrossRefPubMed
22. 22.↵
    1. van Aken J,
    2. Lard LR,
    3. le Cessie S,
    4. Hazes JM,
    5. Breedveld FC,
    6. Huizinga TW

    . Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis. Ann Rheum Dis 2004;63:274–9.

    OpenUrlAbstract/FREE Full Text
23. 23.↵
    1. Landewe RB,
    2. Boers M,
    3. Verhoeven AC,
    4. Westhovens R,
    5. van de Laar MA,
    6. Markusse HM,
    7. et al.

    COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002;46:347–56.

    OpenUrlCrossRefPubMed
24. 24.↵
    1. Emery P

    . The Dunlop-Dottridge Lecture: prognosis in inflammatory arthritis: the value of HLA genotyping and the oncological analogy. J Rheumatol 1997;24:1436–42.

    OpenUrlPubMed
25. 25.↵
    1. van Dongen H,
    2. van Aken J,
    3. Lard LR,
    4. Visser K,
    5. Ronday HK,
    6. Hulsmans HM,
    7. et al.

    Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2007;56:1424–32.

    OpenUrlCrossRefPubMed
26. 26.↵
    1. van der Linden MP,
    2. le Cessie S,
    3. Raza K,
    4. van der Woude D,
    5. Knevel R,
    6. Huizinga TW,
    7. et al.

    Long-term impact of delay in assessment of patients with early arthritis. Arthritis Rheum 2010;62:3537–46.

    OpenUrlCrossRefPubMed
27. 27.↵
    1. Grigor C,
    2. Capell H,
    3. Stirling A,
    4. McMahon AD,
    5. Lock P,
    6. Vallance R,
    7. et al.

    Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263–9.

    OpenUrlCrossRefPubMed
28. 28.↵
    1. Axelsen MB,
    2. Eshed I,
    3. Horslev-Petersen K,
    4. Stengaard-Pedersen K,
    5. Hetland ML,
    6. Moller J,
    7. et al.

    A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial. Ann Rheum Dis 2015;74:867–75.

    OpenUrlAbstract/FREE Full Text
29. 29.↵
    1. Schipper LG,
    2. Vermeer M,
    3. Kuper HH,
    4. Hoekstra MO,
    5. Haagsma CJ,
    6. Den Broeder AA,
    7. et al.

    A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry. Ann Rheum Dis 2012;71:845–50.

    OpenUrlAbstract/FREE Full Text
30. 30.↵
    1. Vermeer M,
    2. Kuper HH,
    3. Hoekstra M,
    4. Haagsma CJ,
    5. Posthumus MD,
    6. Brus HL,
    7. et al.

    Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study. Arthritis Rheum 2011;63:2865–72.

    OpenUrlCrossRefPubMed
31. 31.↵
    1. Vermeer M,
    2. Kuper HH,
    3. Moens HJ,
    4. Drossaers-Bakker KW,
    5. van der Bijl AE,
    6. van Riel PL,
    7. et al.

    Sustained beneficial effects of a protocolized treat-to-target strategy in very early rheumatoid arthritis: three-year results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort. Arthritis Care Res 2013;65:1219–26.

    OpenUrlCrossRef
32. 32.↵
    1. Vermeer M,
    2. Kievit W,
    3. Kuper HH,
    4. Braakman-Jansen LM,
    5. Bernelot Moens HJ,
    6. Zijlstra TR,
    7. et al.

    Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry. BMC Musculoskelet Disord 2013;14:350.

    OpenUrlCrossRefPubMed
33. 33.↵
    1. Vermeer M,
    2. Kuper HH,
    3. Bernelot Moens HJ,
    4. Hoekstra M,
    5. Posthumus MD,
    6. van Riel PL,
    7. et al.

    Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort. Arthritis Res Ther 2012;14:R254.

    OpenUrlCrossRefPubMed
34. 34.↵
    1. Rantalaiho V,
    2. Kautiainen H,
    3. Korpela M,
    4. Puolakka K,
    5. Blafield H,
    6. Ilva K,
    7. et al.

    Physicians’ adherence to tight control treatment strategy and combination DMARD therapy are additively important for reaching remission and maintaining working ability in early rheumatoid arthritis: a subanalysis of the FIN-RACo trial. Ann Rheum Dis 2014;73:788–90.

    OpenUrlFREE Full Text
35. 35.↵
    1. Mottonen T,
    2. Hannonen P,
    3. Leirisalo-Repo M,
    4. Nissila M,
    5. Kautiainen H,
    6. Korpela M,
    7. et al.

    Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999;353:1568–73.

    OpenUrlCrossRefPubMed
36. 36.↵
    1. Naranjo A,
    2. Toloza S,
    3. Guimaraes da Silveira I,
    4. Lazovskis J,
    5. Hetland ML,
    6. Hamoud H,
    7. et al.

    Smokers and non smokers with rheumatoid arthritis have similar clinical status: data from the multinational QUEST-RA database. Clin Exp Rheumatol 2010;28:820–7.

    OpenUrlPubMed
37. 37.↵
    1. Sokka T,
    2. Haugeberg G,
    3. Asikainen J,
    4. Widding Hansen IJ,
    5. Kokko A,
    6. Rannio T,
    7. et al.

    Similar clinical outcomes in rheumatoid arthritis with more versus less expensive treatment strategies. Observational data from two rheumatology clinics. Clin Exp Rheumatol 2013;31:409–14.

    OpenUrlPubMed
38. 38.↵
    1. Saevarsdottir S,
    2. Wedren S,
    3. Seddighzadeh M,
    4. Bengtsson C,
    5. Wesley A,
    6. Lindblad S,
    7. et al.

    Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts. Arthritis Rheum 2011;63:26–36.

    OpenUrlCrossRefPubMed
39. 39.↵
    1. Abhishek A,
    2. Butt S,
    3. Gadsby K,
    4. Zhang W,
    5. Deighton CM

    . Anti-TNF-alpha agents are less effective for the treatment of rheumatoid arthritis in current smokers. J Clin Rheumatol 2010;16:15–8.

    OpenUrlCrossRefPubMed
40. 40.↵
    1. Masdottir B,
    2. Jonsson T,
    3. Manfredsdottir V,
    4. Vikingsson A,
    5. Brekkan A,
    6. Valdimarsson H

    . Smoking, rheumatoid factor isotypes and severity of rheumatoid arthritis. Rheumatology 2000;39:1202–5.

    OpenUrlAbstract/FREE Full Text
41. 41.↵
    1. Syversen SW,
    2. Gaarder PI,
    3. Goll GL,
    4. Odegard S,
    5. Haavardsholm EA,
    6. Mowinckel P,
    7. et al.

    High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis 2008;67:212–7.

    OpenUrlAbstract/FREE Full Text
42. 42.↵
    1. Fautrel B,
    2. Granger B,
    3. Combe B,
    4. Saraux A,
    5. Guillemin F,
    6. Le Loet X

    . Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort. Arthritis Res Ther 2012;14:R249.

    OpenUrlCrossRefPubMed